TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15518608
Drug: Atorvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin with mibefradil
Study: 15518608
Drug: Atorvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin with itraconazole
Study: 8354918
Drug: ranitidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine plus amoxicillin plus metronidazole
Study: 3490195
Drug: Propofol, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol, 2.5 mg/kg IV for induction; 7 +/- 2 mg/min continuous infusion for maintenance
Study: 3490195
Drug: Methohexital, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital, 1.5 mg/kg IV for induction; 6 +/- 2 mg/min continuous infusion for maintenance
Study: 27197106
Drug: Electromyographic biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromyographic biofeedback treatment after progressive muscular relaxation training
Study: 22854660
Drug: Quinvaxem (®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinvaxem (®) vaccine
Study: 22854660
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of Quinvaxem (®)
Study: 22854660
Drug: Quinvaxem (®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinvaxem (®) with concomitant measles vaccine
Study: 20488469
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose antibiotic prophylaxis
Study: 20488469
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy (dextranomer/hyaluronic acid copolymer)
Study: 20488469
Drug: Surveillance group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surveillance group on antibiotic treatment only for febrile urinary tract infection
Study: 8097280
Drug: EMD 49980
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 49980 monotherapy
Study: 8097280
Drug: EMD 49980
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 49980 co-administered with levodopa
Study: 2950359
Drug: VAC/FMC chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC/FMC chemotherapy with bromoergocryptine
Study: 2950359
Drug: VAC/FMC chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC/FMC chemotherapy without bromoergocryptine
Study: 2950359
Drug: VAC/FMC chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC/FMC chemotherapy with medroxyprogesterone acetate (MAP)
Study: 2950359
Drug: VAC/FMC chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC/FMC chemotherapy without MAP
Study: 27393139
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate 25 mg/kg TBW/day in two daily doses
Study: 16766279
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide (HCT)
Study: 16766279
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide (HCT) and 5 mg amyloride
Study: 16766279
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide (HCT) and 50 mg spironolactone
Study: 15233245
Drug: Supervised outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised outpatient exercise training program (3 times weekly on non-dialysis days)
Study: 15233245
Drug: Training program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training program with stationary bicycles during HD sessions (3 times weekly)
Study: 9134070
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch plus four smoking cessation sessions with a nurse-practitioner (moderate-intensity condition, MI)
Study: 9134070
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch plus four smoking cessation sessions plus 16 weekly individual cognitive/behavioral relapse-prevention therapy sessions (high-intensity condition, HI)
Study: 3310727
Drug: Nalbuphine (NAL)
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine (NAL) 1.5 mg/kg BW
Study: 3310727
Drug: Nalbuphine (NAL)
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine (NAL) 2.5 mg/kg BW
Study: 3310727
Drug: Fentanyl (FE)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl (FE) 0.005 mg/kg BW
Study: 29344405
Drug: SLT (individualised
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLT (individualised content, typically weekly sessions for 6-8 weeks)
Study: 21681652
Drug: MOXI‐AF (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOXI‐AF (0.5% moxifloxacin ophthalmic solution) dosed twice-daily for 3 days
Study: 21681652
Drug: MOXI‐AF (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOXI‐AF (0.5% moxifloxacin ophthalmic solution)
Study: 17175636
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 500 ml of 50 g/L fructose daily for 3 days after escharectomy
Study: 17175636
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of glucose 1 day after escharectomy for 3 days
Study: 17175636
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 500 ml of 50 g/L fructose
Study: 17175636
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of glucose
Study: 12585341
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 20 mg daily
Study: 9179087
Drug: Lisinopril (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (18 ± 1 mg)
Study: 7866044
Drug: Amodiaquine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (30 mg/kg for 3 days)
Study: 7866044
Drug: Chloroquine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (30 mg/kg for 3 days)
Study: 2475722
Drug: Cifenline (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cifenline (130 mg or 160 mg twice daily)
Study: 176876
Drug: Cholestyramine (12,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (12, 16, or 20 g daily)
Study: 176876
Drug: Neomycin (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin (1, 1.5, or 2 g daily)
Study: 29035887
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of Valeriana officinalis extract (valerenic acid 0.8%)
Study: 29035887
Drug: Placebo (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (an equal dose of vitamin E)
Study: 24607293
Drug: melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin 3 mg/day
Study: 22782199
Drug: Trimethoprim-sulfamethoxazole, 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole, 480 mg, once daily
Study: 22782199
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, 109 colony-forming units, twice daily
Study: 17239698
Drug: Ezetimibe/simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10/20 mg + fenofibrate 160 mg (EZE/SIMVA + FENO)
Study: 12527974
Drug: 6% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% CHO solution
Study: 1561022
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 mg. methylcellulose)
Study: 31141730
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment of MAL DL‐PDT
Study: 31141730
Drug: Two treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two treatments of MAL DL‐PDT (1 week apart)
Study: 31141730
Drug: Two treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two treatments of MAL DL‐PDT
Study: 28429904
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of lutein for 36 weeks
Study: 21671489
Drug: rTMS (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS (10 Hz, 90% motor threshold) combined with citalopram (20 mg/d)
Study: 21671489
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure combined with citalopram (20 mg/d)
Study: 19489241
Drug: 0.1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ropivacaine with 0.5 microg/ml sufentanil (latent group)
Study: 19489241
Drug: 0.15% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% ropivacaine with 0.5 microg/ml sufentanil (active group)
Study: 16221926
Drug: Methylphenidate (NE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (NE agonist)
Study: 16221926
Drug: Tacrine (ACh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (ACh agonist)
Study: 16221926
Drug: Prazosin (NE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (NE antagonist)
Study: 11518072
Drug: Haloperidol (DA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (DA antagonist)
Study: 16221926
Drug: Biperiden (ACh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (ACh antagonist)
Study: 1523161
Drug: Des-glycinamide-[Arg8]vasopressin (DGAVP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Des-glycinamide-[Arg8]vasopressin (DGAVP, 2 mg intranasal)
Study: 1523161
Drug: Oxytocin (OXT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (OXT, 20 IU intranasal)
Study: 28970100
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus three 15-minute sessions per week of one-to-one hand therapy without functional electrical stimulation.
Study: 18378563
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg for 7 days
Study: 18378563
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg for 7 days
Study: 6720317
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg terbutaline intramuscularly
Study: 6720317
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg terbutaline intramuscularly
Study: 6720317
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg terbutaline intramuscularly
Study: 6720317
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg terbutaline inhalation
Study: 26854123
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy (continuation phase)
Study: 26854123
Drug: MDI to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI to pump therapy (continuation phase)
Study: 26854123
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy and MDI
Study: 24424357
Drug: G‐CSF (Filgrastim,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (Filgrastim, Amgen, 300 μg/1.0 mL)
Study: 14663604
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (prednisolone, hydroxyethyl starch, pentoxifylin)
Study: 14663604
Drug: Fibrinogen/LDL-apheresis in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen/LDL-apheresis in patients with plasma fibrinogen >295 mg/dl
Study: 14663604
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy in patients with plasma fibrinogen >295 mg/dl
Study: 27090097
Drug: Single session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session Brief Intervention/Referral to Treatment (BI/RT)
Study: 27090097
Drug: Multi-session Brief
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-session Brief Intervention/Referral to Treatment (BI/RT+)
Study: 25242204
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (2×500 mg/day)
Study: 22897461
Drug: Rosuvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin monotherapy 40 mg/day (R group)
Study: 22897461
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/day combined with fenofibrate 200 mg/day (RF group)
Study: 22897461
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/day combined with ω-3 fatty acids 2 g/day (Rω group)
Study: 17033631
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rhEPO) 40,000 IU weekly intravenous infusion for 12 weeks
Study: 9607691
Drug: 35 microg
Normalized name: Ethinyl estradiol 35 microgram and norethindrone 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 microg ethinyloestradiol + 2 mg cyproterone acetate for 3 months
Study: 8550255
Drug: Pre-exercise glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-exercise glucose polymer (G) and placebo during exercise (G/P)
Study: 8550255
Drug: Glucose polymer
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymer pre-exercise and during exercise (G/G)
Study: 1965645
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg cicletanine
Study: 1965645
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg cicletanine
Study: 82784
Drug: myo-inositol, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: myo-inositol, 500 mg twice a day
Study: 30745383
Drug: Oxfendazole (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxfendazole (0.5, 1, 3, 7.5, 15, 30, or 60 mg/kg body weight)
Study: 28143430
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen (10 mg/kg)
Study: 25818379
Drug: Indication-based off-label
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indication-based off-label medication order scenarios with lower relative expert power
Study: 25818379
Drug: Indication-based off-label
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indication-based off-label medication order scenarios with less appropriate prescriptions
Study: 25818379
Drug: Indication-based off-label
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indication-based off-label medication order scenarios
Study: 21926932
Drug: Tualang honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tualang honey (20 g/d)
Study: 21926932
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin therapy (Femoston 1/5)
Study: 17018340
Drug: Cardiac contractility
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac contractility modulation signals (n = 25, treatment group)
Study: 1286044
Drug: Cisplatin (chemotherapy)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (chemotherapy)
Study: 3702214
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (1.6 g/kg body wt)
Study: 3702214
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (0.8 g/kg body wt)
Study: 27622453
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg every 12 h for 48 h after an initial preoperative dose of parecoxib 40 mg
Study: 27622453
Drug: Saline every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline every 12 h for 48 h after an initial preoperative dose of saline
Study: 22428845
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta (IFNβ) treatment
Study: 20660592
Drug: Self-medication for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-medication for STI symptoms
Study: 14984518
Drug: s(+)-ketamine and
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: s(+)-ketamine and morphine
Study: 14984518
Drug: saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline and morphine
Study: 14564686
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/d and MPA 2.5 mg/d
Study: 14564686
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/d
Study: 8996159
Drug: Paclitaxel (P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (P) administered as a 3-hour infusion at dosages of 100 to 250 mg/m2
Study: 8996159
Drug: Carboplatin (C)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (C) administered over 30 minutes at dosages of 300 to 400 mg/m2
Study: 8996159
Drug: Paclitaxel (P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (P) and Carboplatin (C) administered in different sequences
Study: 8996159
Drug: Paclitaxel (P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (P) at doses < 175 mg/m2
Study: 8996159
Drug: Paclitaxel (P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (P) at doses >= 175 mg/m2
Study: 8996159
Drug: Paclitaxel (P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (P) with P‐T > or = 0.1 mumol/L for < 15 hours
Study: 8996159
Drug: Paclitaxel (P)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (P) with P‐T > or = 0.1 mumol/L for >= 15 hours
Study: 2441152
Drug: Diuretic (frusemide)
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (frusemide)
Study: 29948021
Drug: Sirolimus with
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus with Metformin (Arm A)
Study: 26996929
Drug: Infection requiring
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infection requiring antibiotics before discharge
Study: 19021487
Drug: Outlook intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outlook intervention (discussions of end-of-life preparation and completion)
Study: 11019371
Drug: Diethylstilbestrol diphosphate
Normalized name: Diethylstilbestrol Diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylstilbestrol diphosphate (DES-P) 300 mg daily for 2 weeks
Study: 11019371
Drug: Chlormadinone acetate
Normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormadinone acetate (CMA) 100 mg daily for 2 weeks
Study: 31952501
Drug: Galcanezumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab (both doses)
Study: 25619411
Drug: NLFU +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLFU + SOC (non-contact low-frequency ultrasound therapy combined with standard of care)
Study: 22226517
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with capecitabine (1000 mg/m² twice daily on days 1 to 14 of each cycle) plus oxaliplatin (130 mg/m² on day 1 of each cycle) for 6 months
Study: 22226517
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with capecitabine plus oxaliplatin
Study: 18719041
Drug: Combination antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antipsychotic prescribing (CAP)
Study: 17230206
Drug: Granulocyte-colony-stimulating factor
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony-stimulating factor (G-CSF) at a subcutaneous daily dose of 10 microg/kg for 5 days
Study: 17230206
Drug: Granulocyte-colony-stimulating factor
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony-stimulating factor (G-CSF)
Study: 12162586
Drug: Betaxolol 0.5%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.5%, Non-selective topical beta receptor blockers, Latanoprost 0.005% (in glaucoma patients)
Study: 3203067
Drug: 0.8 of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 of the minimal erythema dose (MED) of UVB for 8 weeks
Study: 3203067
Drug: 0.4 of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 of the minimal erythema dose (MED) of UVB for 8 weeks
Study: 27179257
Drug: Traditional clinic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional clinic-based therapy + computer-based program (Rannan)
Study: 27179257
Drug: Traditional clinic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional clinic-based therapy
Study: 25330012
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy in group I
Study: 20401474
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg per week)
Study: 20401474
Drug: Bevacizumab (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (2.5 mg/kg per week)
Study: 20401474
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg per week) in renal cell carcinoma patients
Study: 20401474
Drug: Bevacizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (5 mg/kg per week) in breast cancer patients
Study: 15327040
Drug: Cannabis extract
Normalized name: Cannabis sativa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis extract (2.5 mg THC and 0.9 mg CBD), dosage escalated from 15 to 30 mg THC over 14 days.
Study: 2107780
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous prostacyclin (epoprostenol)